Becton Dickinson and Co
BDX175.990USD
-2.260-1.27%
Market hours （ET）Quotes delayed by 15 min
50.44BMarket Cap
33.67P/E TTM
More Details of Becton Dickinson and Co Company
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
Company Info
Ticker SymbolBDX
Company nameBecton Dickinson and Co
IPO dateSep 25, 1963
Founded at1906
CEOMr. Thomas E. Polen
Number of employees74000
Security typeOrdinary Share
Fiscal year-endSep 25
AddressOne Becton Drive
CityFRANKLIN LAKES
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code07417-1880
Phone12018476800
Websitehttps://www.bd.com/
Ticker SymbolBDX
IPO dateSep 25, 1963
Founded at1906
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Richard (Rick) Byrd
Mr. Richard (Rick) Byrd
Executive Vice President, President - Interventional Segment
Executive Vice President, President - Interventional Segment
754.64K
-0.32%
Mr. Timothy M. (Tim) Ring
Mr. Timothy M. (Tim) Ring
Independent Director
Independent Director
59.87K
+1.58%
Ms. Shana Carol Neal
Ms. Shana Carol Neal
Chief People Officer, Executive Vice President
Chief People Officer, Executive Vice President
47.02K
-3.86%
Ms. Catherine M. (Cathy) Burzik
Ms. Catherine M. (Cathy) Burzik
Independent Director
Independent Director
14.81K
+6.70%
Mr. Roland Goette
Mr. Roland Goette
Executive Vice President, President - EMEA
Executive Vice President, President - EMEA
14.21K
-8.25%
Mr. Antoine C. Ezell
Mr. Antoine C. Ezell
Executive Vice President, President, North America, Chief Marketing Officer
Executive Vice President, President, North America, Chief Marketing Officer
11.97K
+28.43%
Mr. Michael Feld
Mr. Michael Feld
Executive Vice President, President - Life Sciences
Executive Vice President, President - Life Sciences
9.19K
+38.45%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Director
Independent Director
9.14K
+11.33%
Ms. Michelle Quinn
Ms. Michelle Quinn
Executive Vice President, General Counsel
Executive Vice President, General Counsel
6.93K
+39.80%
Dr. Carrie L. Byington, M.D.
Dr. Carrie L. Byington, M.D.
Independent Director
Independent Director
5.25K
+21.54%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard (Rick) Byrd
Mr. Richard (Rick) Byrd
Executive Vice President, President - Interventional Segment
Executive Vice President, President - Interventional Segment
754.64K
-0.32%
Mr. Timothy M. (Tim) Ring
Mr. Timothy M. (Tim) Ring
Independent Director
Independent Director
59.87K
+1.58%
Ms. Shana Carol Neal
Ms. Shana Carol Neal
Chief People Officer, Executive Vice President
Chief People Officer, Executive Vice President
47.02K
-3.86%
Ms. Catherine M. (Cathy) Burzik
Ms. Catherine M. (Cathy) Burzik
Independent Director
Independent Director
14.81K
+6.70%
Mr. Roland Goette
Mr. Roland Goette
Executive Vice President, President - EMEA
Executive Vice President, President - EMEA
14.21K
-8.25%
Mr. Antoine C. Ezell
Mr. Antoine C. Ezell
Executive Vice President, President, North America, Chief Marketing Officer
Executive Vice President, President, North America, Chief Marketing Officer
11.97K
+28.43%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Medication Delivery Solutions
1.12B
21.19%
Medication Management Solutions
811.00M
15.38%
Pharmaceutical Systems
575.00M
10.91%
Peripheral Intervention
481.00M
9.12%
Integrated Diagnostic Solutions
456.00M
8.65%
Other
1.83B
34.75%
By RegionUSD
Name
Revenue
Proportion
United States
3.11B
58.93%
International
2.16B
41.05%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Medication Delivery Solutions
1.12B
21.19%
Medication Management Solutions
811.00M
15.38%
Pharmaceutical Systems
575.00M
10.91%
Peripheral Intervention
481.00M
9.12%
Integrated Diagnostic Solutions
456.00M
8.65%
Other
1.83B
34.75%
Shareholding Stats
Updated: Thu, Jul 24
Updated: Thu, Jul 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.27%
BlackRock Institutional Trust Company, N.A.
5.16%
State Street Global Advisors (US)
4.88%
T. Rowe Price Investment Management, Inc.
4.39%
T. Rowe Price Associates, Inc.
3.80%
Other
70.50%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.27%
BlackRock Institutional Trust Company, N.A.
5.16%
State Street Global Advisors (US)
4.88%
T. Rowe Price Investment Management, Inc.
4.39%
T. Rowe Price Associates, Inc.
3.80%
Other
70.50%
Shareholder Types
Shareholders
Proportion
Investment Advisor
52.01%
Investment Advisor/Hedge Fund
29.01%
Hedge Fund
3.22%
Research Firm
2.93%
Pension Fund
2.77%
Bank and Trust
1.60%
Sovereign Wealth Fund
1.22%
Individual Investor
0.57%
Insurance Company
0.30%
Other
6.38%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
2852
268.57M
93.70%
-14.10M
2025Q1
2897
269.10M
93.89%
-12.90M
2024Q4
2874
271.53M
94.56%
-4.62M
2024Q3
2787
266.29M
92.14%
-3.20M
2024Q2
2782
261.01M
90.31%
-2.68M
2024Q1
2797
255.99M
88.58%
-10.13M
2023Q4
2783
259.38M
89.78%
-7.79M
2023Q3
2768
264.64M
91.23%
-591.87K
2023Q2
2787
263.29M
90.78%
-570.64K
2023Q1
2795
257.22M
90.56%
-8.75M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
32.31M
11.27%
+4.44M
+15.92%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
14.79M
5.16%
-22.91K
-0.15%
Mar 31, 2025
State Street Global Advisors (US)
13.99M
4.88%
-94.83K
-0.67%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
12.58M
4.39%
+448.64K
+3.70%
Mar 31, 2025
T. Rowe Price Associates, Inc.
10.89M
3.8%
-1.04M
-8.70%
Mar 31, 2025
Geode Capital Management, L.L.C.
6.48M
2.26%
+127.97K
+2.01%
Mar 31, 2025
MFS Investment Management
6.11M
2.13%
+655.88K
+12.02%
Mar 31, 2025
First Eagle Investment Management, L.L.C.
5.52M
1.93%
+1.09M
+24.64%
Mar 31, 2025
Generation Investment Management LLP
5.30M
1.85%
-518.93K
-8.92%
Mar 31, 2025
Morgan Stanley Investment Management Ltd. (UK)
4.96M
1.73%
-737.71K
-12.95%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
iShares U.S. Medical Devices ETF
4.36%
American Century Focused Large Cap Value ETF
3.16%
First Eagle Global Equity ETF
3.14%
T Rowe Price Capital Appreciation Equity ETF
3.11%
Franklin ClearBridge Enhanced Income ETF
2.93%
iShares Large Cap Value Active ETF
2.34%
Running Oak Efficient Growth ETF
1.9%
SPDR S&P Health Care Equipment ETF
1.8%
T Rowe Price Equity Income ETF
1.72%
First Trust Indxx Medical Devices ETF
1.61%
View more
iShares U.S. Medical Devices ETF
Proportion4.36%
American Century Focused Large Cap Value ETF
Proportion3.16%
First Eagle Global Equity ETF
Proportion3.14%
T Rowe Price Capital Appreciation Equity ETF
Proportion3.11%
Franklin ClearBridge Enhanced Income ETF
Proportion2.93%
iShares Large Cap Value Active ETF
Proportion2.34%
Running Oak Efficient Growth ETF
Proportion1.9%
SPDR S&P Health Care Equipment ETF
Proportion1.8%
T Rowe Price Equity Income ETF
Proportion1.72%
First Trust Indxx Medical Devices ETF
Proportion1.61%
Dividend
A total of
5.34B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Jan 28, 2025
BDX.NB Interim Cash Dividend of gross USD 1.04 paid on Mar 31, 2025 going ex on Mar 10, 2025
Mar 10, 2025
Mar 31, 2025
Mar 10, 2025
Nov 07, 2024
BDX.NB Final Cash Dividend of gross USD 1.04 paid on Dec 31, 2024 going ex on Dec 09, 2024
Dec 09, 2024
Dec 31, 2024
Dec 09, 2024
Jul 23, 2024
BDX.NB Interim Cash Dividend of gross USD 0.95 paid on Sep 30, 2024 going ex on Sep 09, 2024
Sep 09, 2024
Sep 30, 2024
Sep 09, 2024
Apr 30, 2024
BDX.NB Interim Cash Dividend of gross USD 0.95 paid on Jun 28, 2024 going ex on Jun 10, 2024
Jun 10, 2024
Jun 28, 2024
Jun 10, 2024
Jan 23, 2024
BDX.NB Interim Cash Dividend of gross USD 0.95 paid on Mar 29, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Mar 29, 2024
Mar 07, 2024
Nov 09, 2023
BDX.NB Final Cash Dividend of gross USD 0.95 paid on Dec 29, 2023 going ex on Dec 07, 2023
Dec 08, 2023
Dec 29, 2023
Dec 07, 2023
Jul 25, 2023
BDX.NB Interim Cash Dividend of gross USD 0.91 paid on Sep 29, 2023 going ex on Sep 07, 2023
Sep 08, 2023
Sep 29, 2023
Sep 07, 2023
Apr 25, 2023
BDX.NB Interim Cash Dividend of gross USD 0.91 paid on Jun 30, 2023 going ex on Jun 08, 2023
Jun 09, 2023
Jun 30, 2023
Jun 08, 2023
Jan 24, 2023
BDX.NB Interim Cash Dividend of gross USD 0.91 paid on Mar 31, 2023 going ex on Mar 09, 2023
Mar 10, 2023
Mar 31, 2023
Mar 09, 2023
Nov 10, 2022
BDX.NB Final Cash Dividend of gross USD 0.91 paid on Dec 30, 2022 going ex on Dec 08, 2022
Dec 09, 2022
Dec 30, 2022
Dec 08, 2022
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
